1. Ahmed M., Al-dossary E., Woodhouse NJY. Macroprolactinomas with suprasellar extension: effect of bromocriptine withdrawl during one or more pregnacies. Fertil Steril. 1992; 58:492.

  2. Battin DA., Marrs RP., Fleiss PM., et al. Effect of sucking on serum prolactin, luteinizing hormone, follicle-stimulating hormone, and estradiol during prolonged lactation. Obstet Gynecol. 1985; 65:785.

  3. Beckers A., Petrossians P., Abs R., et al. Treatment of macroprolactinomas with the long-acting and repeatable form of bromocriptine: a report on 29 cases. J Clin Endocrinol Metab. 1992; 75:275.

  4. Ben-Jonathan N. Dopamine: a rpolactin-inhibiting hormone. Endocrin Rev. 1985; 6:564.

  5. Bevan JS., Webster J., Burke CW., et al. Dopamine agonists and pituitary tumor shrinkage. Endocrin Rev. 1992; 13: 220.

  6. Biller BMK., Baum HBA., Rosentahl DI., et al. Progressive trabecular osteopenia in women with hyperprolactinemia and associated pituitary prolactinomas. J Clin Endocrinol Metab. 1992: 75:692.

  7. Blackwell RE. Hyperprolactinemia. Evaluation and management. Endocrinol Metab Clin North Am. 1992; 21:105.

  8. Blackwell RE. Diagnosis and management of prolactinomas. Fertil Steril. 1985; 43:5.

  9. Blackwell RE., Younger BJ. Long-term medical therapy and follow up of pediatric-adolescent patients with prolactin-secreting macroadenomas. Fertil Steril 1986; 45:713.

  10. Brue T., Lancranjan I., Loovet JP., et al. A long-acting repeatable form of bromocriptine at long-term treatment of prolactin-secreting macroadenomas: a multicenter study. Fertil Steril 1992; 57:74.

  11. Calaf J. Hiperprolactinemias. En Vanrell JA., Calaf J., Balasch J., Viscasillas P. Fertilidad y esterilidad humanas. Salvat (1a). 1992: 133-147.

  12. Calaf J., Cabero A., Webb S., et al. Tratamiento del prolactinoma. Endocrinología. 1985: 32:73.

  13. Calaf J., Massanas J., De Sostos M., et al. Hiperprolactinemia y ovulación. Clin Invest Ginecol Obstet. 1976; 3:151.

  14. Chang RJ. Anovultation of CNS origin. En Carr BR., Blackwell RE. Textbook of reproductive medicine. Appleton & Lange (1a). 1993; 271-277.

  15. Chang RJ. Hyperprolactinemia and menstrual dysfunction. Clin Obstet Gynecol. 1983; 26:736.

  16. Ciccarelli E., Miola C., Grottoli S. Long-term therapy of patients with macroprolactinomas using repeatable injectable bromocriptine. J Clin Endocrinol Metab. 1993; 76:484.

  17. Cook CB., Nippoldt TB., Kletter GB., et al. Naloxone increases the frequency of pulsatile luteinizing hormone secretion in women with hyperprolactinemia. J Cin Endocrinol Metab. 1991; 73:1099.

  18. Corenblum B., Donovan L. The safety of physiological estrogen plus progestin replacement therapy and oral contraceptive therapy in women with pathological hyperprolactinemia. Fertil Steril. 1993; 59:671.

  19. Crosignani PG., Mattei AM., Scardnelli C., et al. Is pregnancy the best treatment for hyperprolactinemia? Hum Reprod. 1989; 4:910.

  20. Daly DC., Kuslis S., Riddick DH. Evidence of short loop inhibition of decidual prolactin synthesis by decidual proteins. Am J Obstet Gynecol. 1986; 155:358.

  21. De Greef WJ., Voogt JL., Visser TJ., et al. Control of prolactin release induced by suckling. Endocrinology. 1987; 121: 316.

  22. Espinos JJ., Rodríguez-Espinosa J., Webb SM., et al. Long-acting repeatable bromocriptine in the treatment of patiens with microprolactinoma intolerant or resistant to oral dopaminergics. Fertil Steril. 1994; 62:926.

  23. Faglia G., Nocieondo P., Travaglini P., et al. Influence of previous bromocriptine therapy on surgery for microprolactinomas. Lancet. 1983; 1:133.

  24. Ginsburg J., Hardiman P., Thomas M. Vaginal bromocriptine - clinical and biochemical effects. Gynecol Endocrinol. 1992; 6: 119.

  25. Glaser B., Nesher Y., Barziliae S. Long-term treatment of bromocriptine-intolerant prolactinoma patients with CV 205-502. J Reprod Med. 1994; 39:449.

  26. Going JJ., Anderson TJ., Battersby S., et al. Proliferative and secretory activity in human breasts during natural and artificial menstrual cycles. Am J Path. 1988; 130:193.

  27. Haro LS., Lee DW., Singh RNP., et al. Glycosilated human prolactin: alterations in glicosylation pattern modify affinity for lactogen receptor and release in prolactin radioimmunoasay. J Clin Endocrinol Metab. 1990; 71:397.

  28. Hattori N., Ishihara E., Ikekubo K., et al. Autoantibody to human prolactin in patients with idiopathic hyperprolactinemia. J Clin Endocrinol Metab. 1992; 75:1226.

  29. Herman V., Fagin J., Gonsky R., et al. Clonal origin of pituitary adenomas. J Clin Endocrinol Metab. 1990; 71:1427.

  30. Hwang PLH., Ng CSA., Cheong ST. Effect of oral contraceptives on oral prolactine: a longitudinal study in 126 normal premenopausal women. Clin Endocrinol. 1986; 24:127.

  31. Ishizuka B., Quigley ME., Yen SSC. Postpartum hypogonadotropism: evidence for increase opioid inhibition. Clin Endocrinol. 1984; 20:573.

  32. Jackson RD., Wortsman J., Malarkey WB. Characterization of a large molecular weight prolactin in women with idiopathic hyperprolactinemia and normal menses. J Clin Endocrinol metab. 1985; 61:258.

  33. Jackson RD., Wortsman J., Malarkey WB. Macroprolactinemia presenting like a pituitary tumor. Am J Med. 1985; 78: 346.

  34. Jaspers C., Benker G., Reinwein D. Treatment of prolactinoma patients with the new non-ergot dopamine agonist roxindol: first results. Clin Investig. 1994; 72:451.

  35. Katz E., Weiss BE., Hassell A., et al. Increased circulating levels of bromocriptine after vaginal compared with oral administration. Fertil Steril. 1991; 55:882.

  36. Kelly DA., Kjiame J., Postel-Vinay MG., et al. The prolactin-growth hormone receptor family. Endocrin Rev. 1991; 12: 235.

  37. Kletzky OA., Vermesh M. Effectiveness of vaginal bromocriptine in treating women with hyperprolactinemia. Fertil Steril. 1989; 51:269.

  38. Klibanski A., Greenspan SL. Increase in bone mass after treatment of hyperprolactinemic amenorrhea. New Engl J Med. 1986; 315:542.

  39. Klibanski A., Zervas NT. Diagnosis and management of hormone-secreting pituitary adenomas. New Engl J Med. 1991; 324:822.

  40. Knigge U., Sleimann I., Matzen S., et al. Histaminergic regulation of prolactin secretion: involvment of serotoniergic neurons. Neuroendocrinology. 1988; 48:527.

  41. Kooy A., De Grees WJ., Vreeburg JTM., et al. Evidence for the involvemente of coticotropin-releasing factor in the inhibition of gonadotropin release induced by hyperprolactinemia. Neuroendocrinology. 1990; 51:261.

  42. Kremer JAM., Thomas CMG., Roland R., et al. Return of gonadotropic function in postpartum women during bromocriptine treatment. Fertil Steril. 1989; 51:622.

  43. Kupersmith MJ., Rosemberg C., Klemberg D. Visual loss in pregnant women with pituitary adenomas. Ann Intern Med. 1994; 121:473.

  44. Lamberts SWJ., Quik RFT. A comparison of the efficacy and safety of pergolide and bromocriptine in the treatment of hyperprolactinemia. J Clin Endocrinol metab. 1991; 72:635.

  45. Lapphon RE., van de Wiel HBM., Brownell J. The effect of two dopaminergic drugs on menstrual function and psychological state in hyperprolactinemia. Fertil Steril. 1992; 58:321.

  46. Larrea S., Scorza A., Valero A., et al. Heterogeneity of serum prolactin throughout the menstrual cycle and pregnancy in hyperprolactinemic women with normal ovarian function. J Clin Endocrinol Metab. 1989; 68:982.

  47. Lengyel AM., Mussio W., Imamura P., et al. Long-acting injectable bromocriptine (Parlodel-LAR) in the chronic treatment of prolactin-secreting macroadenomas. Fertil Steril. 1993; 59:980.

  48. Liu JH., Lee DW., Markoff E. Differential release of prolactin variants in postpartun and early follicular phase women. J Clin Endocrinol Metab. 1990; 71:605.

  49. Markoff E., Sigel MB., Lacour N., et al. Glycosilation selectively alters the biological activity of prolactin. Endocrinology. 1988; 123: 1303.

  50. Markoff E., Lee DW. Glycosilated prolactin is a mayor circulating variant in human serum. J Clin Endocrinol Metab. 1987; 65: 1102.

  51. Markoff E., Lee DW., Hollingsworth DR. Glyscosilated and non-glycosilated prolactin in serum during pregnancy. J Clin Endocrinol Metab. 1988; 67:519.

  52. McNeilly AS., Robinson KA., Houston MJ., et al. Release of oxytocin and prolaction in response to suckling. Br Med J. 1983; 286:257.

  53. Merola B., Colao A., Caruso E., et al. Oral and injectable long-lasting bromocriptine preparations in hyperprolactinemia: comparison of the prolactin lowering activity, tolerability and safety. Ginecol Endocrinol. 1991; 5: 267.

  54. Merola B., Sarnacchiaro S., Colao A., et al. CV 205-502 in the treatment of tumoral and non-tumoral hyperprolactinemic states. Biomed Pharmacother. 1994; 48:167.

  55. Molitch ME. Pathologic hyperprolactinemia. Endocrinol Metab Clin North Am. 1992; 21:877.

  56. Molitch ME. Management of prolactinomas. Ann Rev Med. 1989; 40:225.

  57. Molitch ME. Pregnancy and the hyperprolactinemic woman. New Engl J Med. 1985; 312:1362.

  58. Molitch ME., Elton RL., Blackwell RE., et al. Bromocriptine as primary therapy for prolactin-secreting macroadenomas: results of a prospective multicentric study. J Clin Endocrinol Metab. 1985; 60:698.

  59. Munley WC. Urban RJ., Kitchin JD., et al. Dynamics of pulsatile prolactin release during the postpartum lactational period. J Clin Endocrinol Metab. 1991; 71:287.

  60. Murphy LJ., Murphy LC., Stead B., et al. Modulation of lactogenic receptors by progestins in cultured breast cancer cells. J Clin Endocrinol Metab. 1986; 62:280.

  61. Nagy G., Mulchaney JJ., Neill JD. Autocrine control of porlactin secretion by vasoactive intestinal peptide. Endocrinology. 1988; 122:364.

  62. Nunley WC. Hyperprolactinemia revisited. Infertil Reprod Med Clin North Am. 1995; 6:37.

  63. Pellegrini I., Rasolonjanahary R., Gunz G., et al Resisatance to bromocriptine in prolactinomas. J Clin Endocrinol Metab. 1989; 69:500.

  64. Raabe MA., McCoshen JA. Epithelial regulation of prolactin effects on amniotic permeability. Am J Obstet Gynecol. 1986; 154:130.

  65. Ruiz-Velasco V., Polis C. Pregnancy in hyperprolactinemic women. Fertil Steril. 1984; 41:793.

  66. Samson WK., Bianchi R., Mogc RJ., et al. Oxytocin mediates the hypothalamic action of vasoactive intestinal peptide to stimulate prolactin secretion. Endocrinology. 1989; 124:812.

  67. Sarkar DK. Evidence for prolactin feedback action on hypothalamic oxytocin, vasoactive intestinal peptide and dopamine secretion. Neuroendocrinology. 1989; 49:520.

  68. Sauder SE., Frager M., Case GD., et al. Abnormal patterns of pulsatile luteinizing hormone secretion in women with hyperprolactinemia and amenorrhea: responses to bromocriptine. J Clin Endocrinol Metab. 1984; 59:941.

  69. Schlechte J., Sherman BM., Chapler FK., et al. Long term follow-up of women with surgically treated prolactin-secreting pituitary tumors. J Clin Endocrinol Metab. 1986; 62:1296.

  70. Schlechte J., Sherman B., Halmi N., et al. Prolactin-secreting pituitary tumors. Endocrin Rev. 1980; 1:295.

  71. Schlechte J., Walkner L., Kathol M. A longitudinal analysis of premenopausal bone loss in helathy women and women with hyperprolactinemia. J Clin Endocrinol Metab. 1992; 75:698.

  72. Serri O., Rasio E., Beauregard H., et al. recurrence of hyperprolactinemia afeter selective transphenoidal adenomectomy in women with prolactinoma. New Engl J Med. 1983; 309; 280.

  73. Sherman L., Fisher A., Class E., et al. Pharmacologyc causes of hyperprolactinemia. Seminars Reprod Endocrinol. 1984; 2: 31.

  74. Sisam DA., Sheham JP., Sheela LR. The natural history of untreated microprolactinomas. Fertil Steril. 1987; 48:67.

  75. Sluijmer AV., Lappohn RE. Clinical history and outcome of 59 patients with idiopathic hyperprolactinemia. Fertil Steril. 1992; 58: 72.

  76. Snyder JN., Dekowski SA. The role of prolactin in fetal lungs matturarion. Seminars Reprod Endocrinol. 1992; 10:287.

  77. Sowers M., Corton G., Shapiro B., et al. Changes in bone density with lactation. JAMA. 1993; 269:3130.

  78. Speroff L., Glass RH., Kase NG. The breast. En Speroff L., Glass RH., Kase NG. Clinical Gynecologic Endocrinology and Infertility. Ed. Williams & Wilkins (5a), 1994; 547-560.

  79. Speroff L., Glass RH., Kase NG. Amenorrhea. En Speroff L., Glass RH., Kase NG. Clinical Gynecologic Endocrinology and Infertility. Ed. Williams & Wilkins (5a), 1994; 414-433.

  80. Speroff L., Levin RM., Haning RB., et al. A practical approach for the evaluation of women with abnormal politomography or elevated prolactin levels. Am J Obstet Gynecol. 1979; 135:896.

  81. Tonner D., Schlechte J. Contemporary therapy of prolactin-secreting adenomas. Am J Med Sci. 1993; 306:39.

  82. Veldhuis JD., Evans WS., Johnson MD., et al. Mechanisms that subserve estraiol's induction of increased prolactin concentrations: evidence of amplitude modulation of espontaneous prolactin secretory bursts. Am J Obstet Gynecol. 1989; 161:1149.

  83. Yen SSC. Prolactina en la reproducción humana. En Yen SSC., Jaffe RB. Endocrinología de la reproducción. Ed. Panamericana (3a). 1993: 382-413.